Browsing Tag
Stifel
30 posts
Aspen Neuroscience (ASPE) prices $140.6m IPO at $15 as Parkinson’s therapy enters pivotal development phase
Aspen Neuroscience has priced its Nasdaq initial public offering at $15 per share, the bottom of its proposed range, as it prepares to advance the investigational Parkinson's disease cell therapy sasineprocel into Phase 3 testing. The financing extends the company's expected operating runway into the second half of 2028, but its clinical programme remains expensive, and the company expects to require additional capital before development is complete.
Boston Scientific’s cyberattack knocks its 2026 outlook off course
Manufacturing, order fulfilment and shipping have been restored, but the medical-device group still cannot quantify the full financial damage and will reset expectations with third-quarter results.
Marvell hands Google $12.2bn warrant to close hyperscaler custom silicon sweep
Marvell's $12.2bn Google warrant vests only against $120bn in cumulative custom silicon revenue, six times its current data centre run rate through fiscal 2033.
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
SLB (NYSE: SLB) jumps 11% as data centers widen the growth story
SLB stock jumped 11% after a Q2 earnings beat. Can ChampionX, offshore recovery and data-centre growth sustain the rerating?
MaxLinear (NASDAQ: MXL) slides 22% as AI expectations outrun its Q2 beat
MaxLinear stock fell 22% despite strong Q2 results. Can optical AI growth, rising margins and Q3 guidance justify MXL’s valuation?
Eos Energy (NASDAQ: EOSE) surges 21% after Golden Dome Z3 prototype award from Pentagon
Eos Energy (NASDAQ: EOSE) surges 21% after winning a multi-million-dollar Golden Dome prototype contract from the Department of War, referenced by Trump.
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
Penguin Solutions (PENG) delivers Q3 fiscal 2026 double beat, raises FY26 revenue growth to 22% on agentic AI demand as Integrated Memory jumps 111%
Penguin Solutions (PENG) posts Q3 double beat, raises FY26 revenue growth to 22% on agentic AI demand. Shares up 8.5% AH, Integrated Memory jumps 111%.
ITG lands a $312m IPO, but the $16 price reveals what investors would not pay
ITG priced its Nasdaq initial public offering below the proposed range, raising $312.2 million as investors weighed broadband growth against debt, weaker margins and customer concentration.